Spatial immune profiling of bone-metastatic castration-resistant prostate cancer reveals radium-223 immunomodulates the bone-tumor microenvironment
This study does not report the clinical results of a clinical trial, but it does use samples from a completed clinical trial that is registered with clinicaltrials.gov (NCT02135484).
Authors
- Theocharis Panaretakis (ORCID: https://orcid.org/0000-0001-5754-6950)
- Yibo Fan (ORCID: https://orcid.org/0000-0003-2523-8261)
- Patricia Troncoso
- Sue-Hwa Lin
- Paul G. Corn
- Jaffer A. Ajani
- Miao Zhang
- Guoyu Yu
- Suyu Liu
- Devaki Shilpa Surasi
- Guocan Wang
- Christopher J. Logothetis
Institutions
- The University of Texas MD Anderson Cancer Center (US)
Publication Details
- Journal
- Prostate Cancer and Prostatic Diseases
- Published
- 2025-12-26
- DOI
- https://doi.org/10.1038/s41391-025-01069-1
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- U.S. Department of Defense
- Cancer Prevention and Research Institute of Texas
- National Institutes of Health
- University of Texas MD Anderson Cancer Center
- DOD Prostate Cancer Research Program